Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer

被引：14

作者：

Cartwright, Thomas H. ^{[1
]}

Genther, Renee ^{[1
]}

机构：

[1] Ocala Oncol, Ocala, FL 34474 USA

来源：

CLINICAL COLORECTAL CANCER | 2008年 / 7卷 / 03期

关键词：

epidermal growth factor receptor inhibitors; FOLFIRI; FOLFOX; monoclonal antibodies; rash;

D O I：

10.3816/CCC.2008.n.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The administration of monoclonal antibodies (MoAbs) can result in infusion reactions of various grades; severe reactions are seen in approximately 3% of patients after infusions of cetuximab (fatalities occur in approximately 0.1% of patients). We report a case of a patient who had a severe reaction to cetuximab (a murine MoAb) who then received panitumumab (a human MoAb) and tolerated it without any infusion reaction.

引用

页码：202 / 203

页数：2

共 5 条

[1]

*AMGEN INC, 2007, VECT PANT PRESCR INF

[2] Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab [J].